Skip to main content
. 2022 Jun 2;10(6):1303. doi: 10.3390/biomedicines10061303

Figure 4.

Figure 4

Serious adverse events among included biologics and small-molecule inhibitors. The meta-analysis illustrated no increase in serious adverse events compared with placebo among our included active treatments.